Key takeaways Researchers have examined how format-tuning bispecific T cell engagers (BTEs) boosts therapeutic efficacy against clear cell renal cell carcinoma (ccRCC). Using a novel persistent multivalent T cell engager (PMTE) to enhance cell avidity and tumor targeting, they tackle challenges like low plasma half-life, poor tumor retention, and antigen…
Andrea Candelli29 January 2025